Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$161.01 - $317.85 $239,099 - $472,007
1,485 Added 3.62%
42,548 $13.5 Million
Q3 2023

Nov 08, 2023

BUY
$164.66 - $218.08 $11,526 - $15,265
70 Added 0.17%
41,063 $6.94 Million
Q2 2023

Aug 11, 2023

BUY
$176.32 - $240.22 $5.74 Million - $7.82 Million
32,550 Added 385.53%
40,993 $8.89 Million
Q1 2023

Jun 14, 2023

SELL
$161.33 - $204.36 $3,226 - $4,087
-20 Reduced 0.24%
8,443 $1.53 Million
Q1 2023

May 11, 2023

SELL
$161.33 - $204.36 $3,226 - $4,087
-20 Reduced 0.24%
8,443 $1.53 Million
Q4 2022

Jun 14, 2023

BUY
$191.53 - $236.82 $3,830 - $4,736
20 Added 0.24%
8,463 $1.66 Million
Q4 2022

Feb 07, 2023

BUY
$191.53 - $236.82 $21,068 - $26,050
110 Added 1.32%
8,463 $1.66 Million
Q3 2022

Nov 08, 2022

BUY
$123.79 - $277.42 $61,895 - $138,710
500 Added 6.37%
8,353 $1.88 Million
Q4 2021

Feb 08, 2022

SELL
$110.64 - $159.4 $110 - $159
-1 Reduced 0.01%
7,853 $1.03 Million
Q3 2021

Nov 08, 2021

BUY
$101.2 - $125.87 $34,408 - $42,795
340 Added 4.52%
7,854 $961,000
Q2 2021

Aug 10, 2021

BUY
$107.45 - $135.95 $114,864 - $145,330
1,069 Added 16.59%
7,514 $857,000
Q1 2021

May 10, 2021

SELL
$95.46 - $133.08 $35,320 - $49,239
-370 Reduced 5.43%
6,445 $775,000
Q4 2020

Feb 08, 2021

SELL
$75.23 - $109.23 $10,532 - $15,292
-140 Reduced 2.01%
6,815 $692,000
Q3 2020

Nov 09, 2020

BUY
$71.31 - $109.74 $86,998 - $133,882
1,220 Added 21.27%
6,955 $538,000
Q2 2020

Aug 07, 2020

BUY
$62.14 - $117.21 $128,940 - $243,210
2,075 Added 56.69%
5,735 $639,000
Q1 2020

May 05, 2020

BUY
$60.41 - $115.92 $221,100 - $424,267
3,660 New
3,660 $264,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track State Board Of Administration Of Florida Retirement System Portfolio

Follow State Board Of Administration Of Florida Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Board Of Administration Of Florida Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on State Board Of Administration Of Florida Retirement System with notifications on news.